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Abstract The goal of this investigation was to develop and demonstrate a polymer/paclitaxel self-
assembly (PTX-SA) formulation. Polymer/PTX-SAs were screened based on smaller size of formulation
using dynamic light scattering analysis. Additionally, fluorescence microscopy and flow cytometry studies
exhibited that polyvinylpyrrolidone (PVP)-based PTX-SAs (PVP/PTX-SAs) had superior cellular
internalization capability in MCF7 and MDA-MB-231 breast cancer cells. The optimized PVP/PTX-
SAs exhibited less toxicity to human red blood cells indicating a suitable formulation for reducing
systemic toxicity. The formation of PVP and PTX self-assemblies was confirmed using fluorescence
quenching and transmission electron microscopy which indicated that the PVP/PTX-SAs were spherical in
shape with an average size range of 53.81 nm as detected by transmission electron microscopy (TEM).
FTIR spectral analysis demonstrates incorporation of polymer and paclitaxel functional groups in PVP/
PTX-SAs. Both proliferation (MTS) and clonogenic (colony formation) assays were used to validate
superior anticancer activity of PVP/PTX-SAs in breast cancer cells over paclitaxel. Such superior
anticancer activity was also demonstrated by downregulation of the expression of pro-survival protein
(Bcl-xL), upregulation of apoptosis-associated proteins (Bid, Bax, cleaved caspase 7, and cleaved PARP)
and β-tubulin stabilization. These results support the hypothesis that PVP/PTX-SAs improved paclitaxel
delivery to cancer cells.
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1. Introduction
Breast cancer (BC) remains the most commonly diagnosed cancer
among women in the United States1. The most recent data on
cancer incidence, mortality, and survival by the American Cancer
Society estimated that there will be 63,410 in situ cases and
252,710 invasive cases with 40,610 deaths occurring in the US in
20171. Paclitaxel (PTX), is a natural compound derived from the
bark of Taxus Brevifolia, antimicrotubule and well-established
chemotherapeutic agent, which exhibits a broad spectrum of
anticancer activity against breast cancer, prostate cancer, leukemia,
non-small cell lung cancer, and ovarian cancer2,3. Due to its
hydrophobicity, it is often formulated with Cremophor EL in
ethanol solution, i.e., Taxol®, which limits clinical use due to its
adverse side effects, such as increased risk for fatal hypersensi-
tivity reactions4, non-linear pharmacokinetics5, prolonged periph-
eral neuropathy6, and myelosuppression7, leading to less
bioavailability at the tumor site and therefore reduced efficacy
for its action against tumor cells6,8,9. Other common side effects of
PTX treatment include vomiting, nausea, loss of appetite, and joint
pain.
In order to circumvent these side effects, various alternative
nanoparticle-based PTX formulations were developed. One of the
most widely used formulations is Abraxane®, which is a Cremo-
phor-free and albumin-bound paclitaxel nanoparticle formulation
(diameter ~120 nm), developed as an alternative formulation to
PTX (Taxol®)2. This serum albumin bound PTX nanoformulation
is approved by the US Food and Drug Administration for the
treatment of breast, lung and pancreatic cancer. This formulation
facilitates crossing across endothelial layers of cells and achieves
33% higher PTX concentration at the tumor site10. Additionally,
Abraxane® was able to increase the maximum tolerated dose
(MTD) by 70–80% compared to PTX. Another PTX nanoformula-
tion, Genexol PM® was approved in South Korea for first line
treatment for metastatic or recurrent breast cancer, non-small cell
lung cancer, and also used in combination with carboplatin for
ovarian cancer. It is a polymeric micellar formulation of poly-
ethylene glycol (PEG), poly(D,L-lactide), and PTX. NK-105 (block
copolymer of PEG and polyaspartate modified with 4-phenyl-1-
butanol with PTX) is another nanoparticular micellar formulation
that has entered phase III clinical trial for metastatic and recurrent
breast cancer. NK-105 exhibits prolonged circulation, enhanced
area under the curve (AUC) by 20 times in contrast to PTX and
also had higher antitumor activity11. Other clinically used (or
under clinical development) PTX formulations/nanoformulations
include Paclical® (paclitaxel combined with Oasmia's excipient
technology XR17)12, Lipusu® (paclitaxel liposome)13, paclitaxel
injection concentrate for nanodispersion (PICN)14, SB05 (posi-
tively charged liposome embedded with paclitaxel)15, LEP-ETU
(liposome-entrapped paclitaxel)16, and Triolimus (micelle contain-
ing paclitaxel, rapamycin and 17-AAG)17. Self-assembly and solid
dispersion techniques were a common approach to generate these
clinically relevant PTX nanoformulations.
The goal of this study was to develop a PTX nanoformulation
using a polymer-based self-assembly technique, using a polymer
excipient already in use in the pharmaceutical industry. The self-
assembly process is a well-established, simple, and rapid fabrication
method to generate nanosized architecture materials for drug delivery
applications18–20. We selected 8 biocompatible polymers for gen-
erating self-assembled polymer/PTX nanoformulations. Table 1
provides structures of polymers used in this study. Among those,
Poloxamer 188 [a nonionic copolymer containing hydrophobic poly
(propylene oxide) (PPO) and two hydrophilic poly(ethylene oxide)
(PEO) units] is widely used for generating micelles by the self-
assembling technique where the PEO units align at the outer lining
and PPO falls in the inner core leading to the formation of micelle
above the critical micellar concentration. We expect polymeric
micelles will be formed using Poloxamer 18821. Whereas, the other
seven polymers were commonly used as drug delivery carriers for
generating solid dispersions or polymeric nanoparticles22–24. The
motive of this study is to minimize any other external agents being
added for the formulation development. Self-assembly is a process
where the various components are held together by inter-particulate
assembly25. There are reports stating that synergistic interactions
between self-organizing particles and a self-assembling matrix
material can lead to hierarchically ordered structures26. Accordingly,
we developed nanostructured formulations of hierarchical order
using PTX and various polymers without any external reagents or
binders. Such self-assembly formulations may have the potential to
circumvent the shortcomings of PTX and provide advantages such
as: ease of preparation; smaller particle size; an efficient binding
ability to PTX; and enhanced particle uptake in cancer cells. In this
investigation, we report an optimized PVP/PTX-SA formulation with
enhanced cellular uptake and superior in vitro cytotoxicity in breast
cancer cells, compared to PTX.
2. Materials and methods
2.1. Materials
All laboratory reagents, solvents, and chemicals were purchased
from Sigma–Aldrich Co. (St. Louis, MO, USA) or Fisher
Scientific (Pittsburgh, PA, USA) unless otherwise mentioned. Cell
culture plastics were purchased from Sarstedt, Inc. (Newton, NC,
USA). All chemicals were used as received without any further
purification.
2.2. Cell culture, growth conditions and treatment
Breast cancer cell lines (MCF7 and MDA-MB-231) were obtained
through American Type Culture Collection (Manassas, VA, USA)
and stored as low passage frozen aliquots upon cell culture
expansion. These cell lines were thawed and cultured under sterile
conditions for all experiments (o3–4 months after thawing). Both
cell lines were cultured in Dulbecco's modified Eagle's medium-
high glucose (DMEM-Hi) medium containing 4.5 g/L of glucose,
10 nmol/L of nonessential amino acids, 100 nmol/L of sodium
pyruvate, 1× antibiotic/antimycotic (Gibco, Thermo Fisher Scien-
tific, Grand Island, NY, USA) and 10% heat-inactivated fetal
bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA,
USA) at 37 °C in a humidified atmosphere (5% CO2 and 95%
air condition, ThermoScientific, Waltham, USA). In all cell culture
experiments, monodispersed cell lines after trypsinization were
plated on either 6-, 12-, or 96-well plates, and were allowed to
adhere overnight to the plate before implementing treatments.
2.3. Preparation of polymer-PTX-SAs (Poly/PTX-SAs)
Eight polymer-based drug delivery vehicles, such as polyvinyl
alcohol (PVA, MW 31,000–50,000), polyvinylpyrrolidone (PVP,
MW 40,000), polyethyleneimine (PEI, MW 25,000), poly(methyl
vinyl ether-alt-maleic hydrochloride) (PMEAVH, MW 216,000),
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poly(allylamine hydrochloride) (PA-HCl, MW 17,500), Poloxamer
188 (Kolliphor® P 188, P188), polyacrylic acid (PAA, MW
100,000), and Povacoat F (polyvinyl alcohol-acrylic acid-methyl
methacrylate copolymer: Type F, MW 40,000, a gift sample
received from Daido Chemical Co., Osaka, Japan), were used in
the PTX self-assembly formation. The self-assembly formation
technique is followed by solvent evaporation. Briefly, 5 mg of
polymer was dissolved in 1 mL aqueous medium in 8 mL glass
vial under continuous stirring at 400 rpm on a stir plate (Bench-
mark digital magnetic hotplate stirrer, ABC Scientific, Glendale,
CA, USA). To this solution, 100 µL of PTX dissolved in acetone
(1 mg/mL) was added slowly (dropwise) and the speed increased
to 900 rpm. The obtained solution was stirred overnight to
evaporate the acetone resulting in formation of self-assembled
nanoparticles comprised of assembled polymer chains and PTX,
i.e., referred to as polymer/paclitaxel self-assemblies (Poly/PTX-
SAs). The resultant Poly/PTX-SAs solution was kept refrigerated
and used within a week. For all in vitro cell culture experiments, a
fresh batch of Poly/PTX-SAs was used in order to protect PTX
activity in the formulations.
2.4. Characterization of Poly/PTX-SAs
2.4.1. Particle size and zeta potential
The average particle size, particle distribution and zeta potential of
the prepared PTX-SA formulations were measured by the dynamic
light scattering (DLS) principle using Zetasizer (Nano ZS, Mal-
vern Instruments, Malvern, UK). These measurements were done
as previously reported27, briefly 50 µL of freshly prepared Poly/
PTX-SA nanoparticle suspension was dispersed in deionized water
and was probe sonicated (VirSonic Ultrasonic Cell Disrupter 100,
VirTis) for 30 s. Probe sonication procedure is commonly applied
in formulation development for the formation of nanoparticles and
Table 1 Polymers employed for self-assembling PTX to produce polymer/PTX self-assembly nanoparticles.
No. Name of polymer Structure of Polymer
1 Polyvinyl alcohol (PVA)
2 Polyethyleneimine (PEI)
3 Poly(methyl vinyl ether-alt-maleic hydrochloride) (PMEAVH)
4 Poly(allylamine hydrochloride) (PA-HCl)
5 Polyacrylic acid (PAA)
6 Povacoat F (polyvinyl alcohol-acrylic acid-methyl methacrylate) copolymer
7 Polyvinylpyrrolidone (PVP)
8 Poloxamer 188 (P188)
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homogeneous solution which minimizes the interaction of aggre-
gated nanoparticles and to disperse well but not to break particles
into smaller particles. Additionally, a short span of sonication is
subjected to ensure that particle suspension is homogeneous in
nature. Particle size measurements were performed in water for
3 min at 25 °C. An average diameter and distribution of particle
size was determined from triplicated runs. In a similar way, zeta
potential was measured using nanoparticle suspension diluted with
1× phosphate-buffered saline (PBS). The zeta potential of nano-
particle formulations was also based on the average of 3 readings
(each reading ¼ 30 runs).
2.4.2. Transmission electron microscopy
The size and surface morphology of PVP/PTX-SAs were inves-
tigated by JEOL 200EX transmission electron microscopy (TEM,
JEOL Ltd, Tokyo, Japan) operating at 80 kV. For this, 100 µL of
PVP/PTX-SA suspension was dispersed in 1 mL of water, were
probe sonicated for 30 s. On a 150 mesh standard TEM grid
(Electron Microscopy Sciences, PA, USA), a 20 μL aliquot of the
PVP/PTX-SAs was carefully placed on the shiny side of the grid.
It was stained using 2% (w/v) uranyl acetate solution. The excess
amount of formulation was removed using filter paper and the grid
was allowed to air dry followed by imaging using an AMT camera
at a direct magnification of 100,000× under the TEM system.
2.4.3. Spectral analysis
A Fourier transform infrared (FTIR) spectrum was employed to
determine the formation of PVP/PTX-SAs. FTIR spectral data
were acquired on the Universal ATR sampling Accessory plate
using a Spectrum 100 FTIR spectrophotometer (Perkin Elmer,
Waltham, MA). Samples of PVP/PTX-SAs was lyophilized to
obtain dry solid particles using a Labconco Freeze Dry System
(–48 °C, 133×10-3 m Bar; Labconco, Kansas City, MO, USA).
The samples (PTX, PVP and PVP/PTX-SA) were placed on the tip
of the ATR objective and spectra were obtained between 4000 and
650 cm1.
2.5. Fluorescence binding
Self-assembly formation of polymer and PTX was determined on a
SpectraMax Plus plate reader (Molecular Devices, Sunnyvale, CA,
USA). For this study, PTX conjugated dye (PTX, Oregon Green
488 conjugate with a Flutax-2, Molecular Probes Inc., Life
Technologies, OR, USA) was used, from which the fluorescence
quenching of Oregon green 488 on PTX was achieved by titrating
with polymeric/surfactant solutions. Intrinsic fluorescence of
5 µg/mL PTX solution in 1× PBS was titrated with 0–80 µg/mL
of PVP solution. The decay in fluorescence was studied by
exciting at 496 nm and emission between 450–600 nm.
2.6. Hemolysis assay
A healthy human donor blood with sodium citrate as anticoagulant
was purchased from Interstate Blood Bank Inc. (Memphis, TN,
USA) for the hemolysis test. The hemoglobin released from red
blood cells (RBCs) upon treatment with 10 µg PTX/well or 10 µg
PTX equivalent/well of Poly/PTX-SAs was quantitatively measured
as described earlier28,29. For this assay, 200 µL of RBC suspension
(8×105) was incubated with 10 µg/well of PTX or Poly/PTX-SAs (of
similar concentration as PTX) and placed in an incubator for 60 min
at 37 °C. Sodium dodecyl sulfate (SDS, 1 mg/mL) was used as a
positive control (100% lysis) while 1× PBS was used as a negative
control (0%). After the incubation for 1 h, hemoglobin released into
medium (supernatant, 100 µL) was collected, transferred to a 96-well
plate, and absorbance was measured at 510 nm using a plate reader
(Cytation 3 imaging reader, BioTeK Winooski, VT, USA). To
further confirm these results qualitatively, a few drops of the treated
RBC solution was smeared on a glass slide and images were
captured using EVOS® FL Imaging System (AMF4300, Life
Technologies, Carlsbad, CA, USA). The percentage of hemolysis
was calculated using the Eq. (1):





For this study, previously reported methods were employed for
qualitative and quantitative uptake of coumarin 6 loaded in Poly-
SAs in cancer cells30,31. In this experiment, freshly prepared
coumarin 6-loaded Poly-SAs were generated by procedures
described in Section 2.3. The polymer to dye ratio was kept
50:1 (5 mg of polymer and 100 µg of dye). Breast cancer cell lines,
MCF7 and MDA-MB-231 (5000 cells/well with 100 µL media/
well in 96-well culture plates) were seeded at 500,000 cells/well
with 2 mL medium in a 6-well plate. Cells were allowed to attach
to the plate and media was replaced with 5 µg (dye equivalent)
coumarin 6-loaded Poly-SAs. To ensure the stability of coumarin
6 dye, such that it does not leach out of the nanoassemblies, a
shorter incubation time of 3 h was selected. Since it is a
comparative experiment among 8 different formulations to identify
Figure 1 Particle size and zeta potential of Poly/PTX-SAs. 50 μL of
Poly/PTX-SAs were dispersed in 1 mL distilled water or 1× PBS and
probe sonicated for 30 s. These solutions were measured for particle
size and zeta potential using dynamic light scattering at 25 °C using
Zetasizer (Nano ZS, Malvern Instruments, Malvern, UK). (A) Average
particle size of polymer PTX-SAs was measured for 3 min exhibiting
the smallest size for PVP/PTX-SAs (140.53 nm). (B) Zeta potential of
Poly/PTX-SAs was measured in 1× PBS and average of 3 readings
(each reading ¼ 30 runs) were presented. Data represented as an
average of three readings that were recorded independently with error
bars represented as standard error of the mean.
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the best one, we have not considered coumarin 6 leaching from
formulations. After a 3 h treatment, cells were washed twice with
1× PBS to remove the excess coumarin 6-loaded Poly-SAs that
may be adhered to the surface of the culture plate or cells. Then,
DMEM phenol red free medium was added to these treated cells
and uptake of coumarin 6-loaded Poly-SAs in cells was imaged
using EVOS® FL Imaging System (AMF4300, Life Technologies,
Carlsbad, CA, USA). Furthermore, the quantitative uptake of
coumarin 6-loaded Poly-SAs in cells was determined by trypsiniz-
ing, centrifuging and collecting the cells in 2 mL media, which
were injected (50 µL cell suspension) into an Accuri C6 Flow
Cytometer (Accuri Cytometer, Inc., Ann Arbor, MI, USA).
Quantitative uptake of couamrin 6-SAs measurements were
acquired using the fluorescence levels in FL1 channel (488
excitation, Blue laser, 530715 nm, FITC/GFP). Standard devia-
tions were calculated from 3 replicates.
2.8. Cell viability assay
A calorimetric CellTiter 96® aqueous one solution cell prolifera-
tion assay (MTS assay, Promega, Madison, WI) was used to
examine the effect of PTX-SAs on cell proliferation of breast
cancer cells. The measurement of cell viability is based on the
ability of viable cells to cleave the tetrazolium compound 3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophe-
nyl)-2H-tetrazolium, salt by mitochondrial dehydrogenase. Briefly,
MCF7 and MDA-MB-231 (5000 cells/well with 100 µL media/
well in 96-well culture plates) were seeded in regular growth
medium and allowed overnight cells to attach to the wells. These
cells were treated with 1.25, 2.5, 5, 10, and 20 nmol/L PTX or
PVP/PTX-SAs in order to determine the cell proliferation cap-
ability. Cell lines with no treatment served as controls, respec-
tively. After 48 h of treatment, 20 µL of MTS reagent solution was
added to the cells and incubated for 2 h at 37 °C. Absorbance
reading was recorded at 490 nm using a Microplate Reader
(BioTeK Cytation 3, Winooski, VT, USA). Data were plotted
using cell proliferation against concentration of treatment, where
the proliferation of PVP/PTX-SAs and PTX was determined by the
percentage of the absorbance of treated cells to the absorbance of
control or non-treated cells. All the experiments were performed at
least in triplicates.
2.9. Clonogenic assay
Clonogenic assay was performed to investigate the effect of PVP/
PTX-SAs on breast cancer cells to form colonies as an in vitro cell
survival assay based on the ability of a single cell to grow into a
colony. For this study, breast cancer cells were seeded (250 cells/
well) in 12-well plate and allowed 2 days to attach and start
generating smaller colonies. Then, these initiated cell colonies
were treated with 0.25, 0.5 and 1 nmol/L PTX and PVP/PTX-SAs
for two weeks. Visible colonies were fixed, stained with hematox-
ylin and manually counted (~50 cells considered as a colony) as
discussed earlier27,32. The results are presented as percentage of
colonies as compared to the control (non-treated cells).
2.10. Tubulin stabilization assay
β-Tubulin stabilization assay was performed by immunofluores-
cence assay to examine PTX inherent tubulin binding and
alteration efficacy of PVP/PTX-SAs27. Briefly, 25,000 cells/well
were cultured in 4-well chamber slides and cultured overnight to
attach to a glass slide before treatment with 5 nmol/L PTX or PVP/
PTX-SAs or respective controls (DMSO or polymer) for 8 h. After
treatment, cells were rinsed with 1× PBS for 3 min three times,
fixed with ice-cold methanol for 20 min, blocked with 10% goat
serum for 1 h. Then, cells were immunostained overnight with β-
tubulin antibody (1:50 cell signaling, #CS2146) at 4 °C on a
rocker with 20 oscillations/min. After incubation with primary
antibody, cells were rinsed three times with 1× PBS then probed
with Alexa Fluor 488 goat anti-rabbit secondary antibody (1:200,
# A11008, Thermo Fisher Scientific, Waltham, USA) for 1 h.
DAPI was used to counterstain nuclei of cells. Finally, the
polymerization of tubulin in cells was visualized under a laser
confocal microscope (Carl Zeiss LSM 710, Thornwood, NY,
USA) with a 40×0.7NA oil immersion objective.
Figure 2 Evaluation of hemocompatibility behavior of Poly/PTX-SAs. (A) Hemocompatibility was assessed using human red blood cells by
treating them for 1 h with PTX or Poly/PTX-SAs. In this experiment, sodium dodecyl sulfate (SDS, 1 mg/mL) served as a positive control (100%
lysis) while 1× PBS was used as a negative control (0%). The percentage of hemolysis was calculated using our previously reported method.
(B) Images of treated red blood cells on glass slide were captured using EVOS® FL Imaging System (AMF4300, Life Technologies, Carlsbad, CA,
USA). PVP/PVA-PTX-SAs demonstrate intact membrane morphology in RBCs as PBS, whereas PTX and other Poly/PTX-SAs exhibited toxic
behavior by disintegrating membrane structure of RBCs (Bar¼25 μm). Data represented as mean7standard error of the mean (n¼3), *Po0.05.
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2.11. Immunoblot analysis
For immunoblot analysis, MDA-MB-231 cells (1 × 106 in 10 mL
medium) were seeded in a 100 mm culture dish and treated with
10 nmol/L PTX or PVP/PTX-SAs or respective control (DMSO
and PVP) for 48 h. These cells were lysed with Cell LyticTM M
reagent (Sigma–Aldrich Co., St. Louis, MO, USA), the protein
concentrations were measured, and equal concentrations of total
protein were separated by SDS-PAGE, and the Western blotting
methods were followed as described previously33,34. Primary
antibodies [β-actin (#4967), BAX (#2772), BID (#2003), cleaved
caspase7 (#9491), BCL-XL (#2762), cleaved PARP (#9548) and
MDR1/ABCB1 (#13342)] (Cell Signaling Technologies, Danvers,
MA, USA) and secondary antibody (horseradish peroxidase-
conjugated goat anti-mouse #7076P2 or goat anti-rabbit #7074P2
secondary antibody) (Cell Signaling) were used in this study. The
specific protein bands were detected using enhanced Lumi-Light
Detection Kit reagent under a Biorad ChemiDocTM MP System
(Biorad, Hercules, CA, USA).
2.12. Statistical analysis
All statistical analyses were performed with GraphPad Prism
5 Software (GraphPad Software, San Diego, CA, USA) using
Student's t-test. The difference was considered to be significant for
P values of o0.05. DLS (particle size and zeta potential),
hemolysis, cellular uptake, and MTS assay data were expressed
as mean 7 standard error of the mean. All graphs were generated
using GraphPad Prism 5 Software.
3. Results
3.1. Development of a suitable Poly/PTX-SA formulation for
breast cancer
A successful self-assembled nanoparticle formulation may deliver
therapeutic agent at the tumor site more efficiently than the parent
PTX drug molecule alone. The selection of such a self-assembly
carrier depends on its physico-chemical and biological character-
istics. Therefore, in this investigation, we used eight commonly
used pharmaceutical delivery vehicles to load PTX by the self-
assembly technique which allows formation of nanoparticles. The
inherent thermodynamic forces direct the nanoparticle formation
without use of external agents. A similar self-assembly process
was previously reported by our group for β-cyclodextrin-curcumin
and poly(β-cyclodextrin)-curcumin assemblies32,35. These self-
assembled nanoparticles are much more stabilized and thus
prevent aggregation and flocculation. To further ensure that
solution is homogeneous in nature we have probe sonicated the
self-assembled nanoparticles36. The formed self-assemblies of
PTX with various polymers produced particle sizes ranging from
140.53 to 358.86 nm which were measured by dynamic light
scattering measurements (Fig.1A). A lower particle size self-
assembly was observed with PVP/PTX-SAs (140.53 7 7.08 nm)
and Povacoat F-PTX-SAs (145.275.33 nm) due to strong PTX
holding capacity within their polymer chain networks. High
positive zeta potential formulation often induces systemic toxicity.
Figure 3 Cellular uptake of Poly/PTX-SAs. (A) Quantitative cellular
uptake evaluation. All the cells were treated with Poly SAs loaded
with coumarin 6 instead of PTX in order to evaluate fluorescent uptake
in cells. BC cells (500,000) were treated with Poly/coumarin 6-SAs
(5 µg dye equivalent formulations) for 3 h. These cells were trypsi-
nized, centrifuged and collected in 2 mL media, which were injected
(50 µL cell suspension) into an Accuri C6 Flow Cytometer (Accuri
Cytometer, Inc., Ann Arbor, MI, USA). Mean fluorescence intensity in
FL1 channel (488 excitation, Blue laser, 530 7 15 nm, FITC/GFP)
was measured. Data represented as mean 7 standard error of the mean
(n ¼ 3), *Po0.05. (B) Qualitative internalization efficiency of Poly/
coumarin 6-SAs in BC cells. In above treatment condition, uptake of
Poly/couamrin 6-SAs in BC cells was viewed using EVOS® FL
Imaging System (AMF4300, Life Technologies, Carlsbad, CA, USA).
Bar equals to 200 μm. This study suggests fluorescence intensity in the
order: PVP4PVA4PMEAVH4Povacoat F4 PA-HCL4PEI4Po-
loxamer 1884PAA coumarin 6-SAs.
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Most of the Poly/PTX-SA exhibited negative zeta potential
(between –4.34 to –13.1 mV, Fig. 1 B) while PA-HCl
(þ9.54 mV) and PEI (þ3.09 mV) exhibited positive zeta potential.
To further screen all these Poly/PTX-SAs for cancer therapeu-
tics, a suitable self-assembly formulation must be hemocompati-
ble. This property is highly recommended for any clinically
applied or approved formulation. The safety profile of PTX-SAs
on RBCs for hemocompatibility was examined at 10 µg/well of
PTX or Poly/PTX-SAs. Results suggests that PVP, PVA, PA-HCl,
and Poloxamer 188 based PTX-SAs exhibited negligible hemo-
lysis (similar to negative control treatment, PBS) while other PTX-
SAs demonstrated higher hemolysis (more than 20% hemolysis)
like a free PTX drug (Fig. 2A). This hemocompatibility behavior
with PVP and PVA is correlated with intact membrane morphol-
ogy in RBCs just like a negative control (PBS) treated RBCs
(Fig. 2B). All other Poly/PTX-SAs exhibited severe influence on
shape and morphology of RBCs (Fig. 2B). PTX alone exhibited
significant toxic behavior by disintegrating membrane structure of
RBCs.
Irrespective of the type of drug formulation, they must interact
and penetrate through the cell membrane of cancer cells, then be
released into the cytosol at sufficient concentrations to induce
therapeutic benefit. Therapeutic outcomes are improved if the
intracellular uptake of nanoparticle is improved. Thus, higher
internalization of formulation in the cells is the key factor to
determine the efficiency of the nanoparticle formulation. The
cellular uptake was conducted using dye-loaded polymer assem-
blies which can be assessed by green fluorescence in cells which
directly reflects the internalization of the formulation. This study
demonstrated an uptake of coumarin 6 pattern in MDA-MB-231
cells as PVP4PVA4PMEAVH4Povacoat F4PA-
HCL4PEI4Poloxamer 1884PAA PTX-SAs, whereas similar
pattern was observed in MCF7 cells with the highest cellular
uptake in PVP/PTX-SA (Fig. 3A). The mean fluorescence
intensities of PVP/PTX-SAs and PVA/PTX-SA were ∼16 and
14; ~10 and 9 times higher in MDA-MB-231 and MCF7,
respectively (Fig. 3A). Fluorescence images of cells provide
further evidence for similar uptake characteristics of polymer
self-assemblies than that observed in flow cytometry. PVP and
PVA self-assemblies were clearly detected in cancer cells all over
the cellular organelles while other polymers show less fluorescence
in these cells (Fig. 3B). However, the higher size range of PVA/
PTX-SA of 358.86 nm, minimized the chances of using it as a
potential nanoformulation. Thus we selected PVP/PTX-SAs for
the rest of the study, as PVP is a better binder for transporting
loaded therapeutics into cancer cells.
From the DLS, hemocompatibility, and cellular uptake studies,
it can be reported that PVP/PTX self-assemblies have the optimal
size and negative charge while maintaining hemocompatibility and
improved cellular uptake in cancer cells that are may be helpful for
Figure 4 Self-assembly formation of PVP/PTX-SAs. A) Self-assembly formation was confirmed by binding potential (quenching) of PTX
conjugated dye (PTX, Oregon Green 488 conjugate (Flutax-2, Molecular Probes Inc., Life Technology, OR, USA)) with PVP solution (5–
80 µg/mL). Fluorescence was studied by exciting at 496 nm and emission between 450–600 nm. (B) FTIR spectra of PVP/PTX-SAs, PTX, and
PVP. The presence of 1033 cm–1 (characteristic PTX peak) and 1270, 1284, 1420 and 1654 cm–1 characteristic PVP peak) confirms the presence of
both PVP and PTX in the self-assembly formation of PVP/PTX-SAs. (C) Schematic and hypothetical structural presentation of PVP/PTX-SAs.
Color, dimensions, assembly are not comparable to synthesized formulation. Morphology of PVP/PTX-SAs imaged by using AMT camera at a
direct magnification of 100,000× under the TEM on a 150 mesh standard TEM grid, stained by 2% w/v uranyl acetate solution. The average
particle size viewed under TEM 53.8172.6 nm. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of this article.)
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cancer therapeutic purposes. Thus, all our further studies described
in this manuscript are focused on PVP/PTX-SAs.
3.2. Characterization of PVP/PTX self-assembly formation
In order to confirm that PVP and PTX form self-assembly
nanoparticles, we utilized PTX-conjugated dye (PTX, Oregon
Green 488 conjugate) for fluorescence quenching assay. In the
first method, to confirm efficient binding of PTX with the PVP, a
quenching study was performed against PTX-conjugated dye
(PTX, Oregon Green 488 conjugate) in 1× PBS solution
(Fig. 4A). Fluorescence quenching reveals possible interaction of
polymer with PTX dye. This is instantaneous process directly
couples/self-assembles PTX to polymer. Such instantaneous par-
ticle formation and integrity was confirmed by hydrodynamic
diameter measurements using DLS. The fluorescence intensity of
PTX dye was diminished with increase of PVP solution. This
directly correlates to the binding potential of PVP with PTX which
indicates successful formation of self-assemblies.
The inclusion of PVP and PTX in PVP/PTX-SAs can be
confirmed using FTIR analysis. The FTIR spectra of the PVP,
PTX, and PVP/PTX-SAs (Fig. 4B) demonstrate that PTX has
distinct visible peaks at 1734 cm–1, 1704 cm–1 and 1645 cm–1 (due
to C ¼ O stretching of amide and ester functionality) which were
not visible in PVP/PTX-SA thus suggesting a possible interaction
of PVP with PTX through these functional groups. Further, in the
PVP/PTX-SAs spectrum, the intensity of the broad band around
3259 cm–1 was reduced suggesting another possible interaction
motif with the alcoholic O–H functionality too. If we look into the
fingerprint region of the FTIR spectrum for the PVP/PTX-SAs
formulation, the sharp peak at 1033 cm–1 confirms the presence of
PTX in the formulation. Lastly, the peaks at 1270, 1284, 1420 and
1654 cm–1 of both PVP/PTX-SA and PTX substantiates the
coexistence of both PVP and PTX in the given formulation. The
FTIR study was performed to confirm the existence of polymer
and PTX in its formulation but not to verify the course of self-
assembly formation between polymer and PTX. Additional
evidence is to examine its nanoparticle formation using TEM for
the size and the morphology of self-assemblies (Fig. 4C). A clear
contrast of self-assembled nanoparticles formation was observed
with positively stained (2% w/v uranyl acetate solution) PVP/PTX-
SAs. From this study, it is evident that the average size of the dry
and stained PVP/PTX-SAs found to be 53.8172.6 nm. DLS data
provides particles in suspension or wet form which always exhibit
higher particle size over TEM measurements. This nanoparticle
observation substantiates and affirms the hydrodynamic size of the
nanoparticles measured by DLS.
3.3. In vitro anticancer potential of PVP/PTX-SAs
The therapeutic efficacy of PVP/PTX-SAs was evaluated in breast
cancer cell lines by MTS viability and colony formation assay32.
Both PTX and PVP/PTX-SAs showed a dose-dependent antiproli-
feration effect (1.25–20 nmol/L) in MCF7 and MDA-MB-231
(Fig. 5A). The control polymer did not show any effect on cell
growth. The in vitro 50% cell growth inhibitory concentration (IC50)
Figure 5 PVP/PTX-SAs significantly inhibit proliferation of breast cancer cells. (A) Breast cancer cells (MCF7 and MDA-MB-231, 5000 cells/
well) were plated in 96-well plate and were treated with PTX or PVP/PTX-SA at a range of concentration 1–20 nmol/L for 48 h. Cell viability was
assessed by MTS assay by measuring absorbance at 490 nm using microplate reader. Relative cell viability was measured (using GraphPad Prism
5 Software) with control (untreated) breast cancer cells, considering as 100%. Data represented as mean 7 standard error of the mean (n ¼ 3),
*Po0.05. (B) Representative phase contrast microscopic images were captured by EVOS® FL Imaging System to evaluate the effect of PVP/PTX-
SAs on the cell morphology. PTX or PVP/PTX-SA concentration was equivalent to 5 PTX nmol/L. Bar equals to 200 μm.
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is the quantitative measure of the toxicity induced by treatment
group on the cells. IC50 values for PTX is 13.12 nmol/L and 12.40
whereas IC50 for PVP/PTX-SAs is 4.68 and 7.26 nmol/L, for MCF7
and MDA-MB-231, respectively. Similarly, images of treated cells
indicate that the inherent anticancer activity of PTX is preserved in
PVP/PTX-SAs (Fig. 5B). In fact, PVP/PTX-SA formulation is more
potent in suppressing cell growth compared to PTX. A similar
superior active performance of PVP/PTX-SAs was achieved in the
colony forming assay, which is another complementary assay to
evaluate anticancer efficacy (Fig. 6). In this study, PVP/PTX-SAs
have shown a significant decrease in colonies and colony density
over PTX for both MCF7 and MDA-MB-231 (Fig. 6A and B). Such
high anti-proliferative and colonogenic potency of PVP/PTX-SAs at
a low effective dose compared to paclitaxel demonstrates that a
lesser concentration of PTX is needed in self-assembly formulations
for effective therapeutic outcomes.
3.4. Molecular activity of PVP/PTX-SAs
At the cellular level, PTX binds to the β-tubulin subunits in
microtubules and induces polymerization of tubulin which disrupts
microtubule dynamics, may causing mitotic arrest and thus cell
death37. To obtain further insight in this aspect of PVP/PTX-SAs,
we performed β-tubulin stabilization using a specific antibody in
immunostaining and imaging by confocal microscopy. A higher
microtubule polymer mass was observed on treatment with PVP/
PTX-SAs, in contrast with PTX (5 and 10 nmol/L) or respective
control groups (DMSO or PVP). Higher microtubule bundles in
cells, suggested by the green fluorescence observed for micro-
tubule staining (Fig. 7A), is due to enhanced antitumor activity of
PVP/PTX-SAs compared to PTX. This behavior was more
prominent even at 10 nmol/L (Data not shown) concentration
with PVP/PTX-SAs indicating the use of PVP/PTX-SAs may
reduce concentrations required to induce anticancer effect.
We performed immunoblot analysis to further understand the
superior anticancer function of PVP/PTX-SAs in breast cancer
cells. Expression of various proteins such as BCL-XL, BID, BAX,
cleaved PARP, cleaved caspase 7, and MDR1 upon treatment with
PTX and PVP/PTX-SAs was assessed (Fig. 7B). The expression of
key pro-survival protein (BCL-XL) was effectively down-regu-
lated by PTX and PVP/PTX-SAs treatment. In addition, expres-
sion of pro-apoptosis proteins (BAX and BID), cleaved PARP, and
cleaved caspase 7, increased following PTX and PVP/PTX-SAs
treatment. These events are more prominent in PVP/PTX-SAs
strongly suggests PVP/PTX-SAs induce apoptosis more pronounc-
edly in comparison to the native drug PTX38. Further,
the effect of treatment on MDR1 protein expression was also
observed. Altogether, we can conclude that PVP/PTX-SAs were
able to stabilize tubulin polymerization and cause intrinsic
differences in molecular effects, which could effectively induce
apoptosis.
Figure 6 PVP/PTX-SAs repress the clonogenic potential of breast cancer cells. (A) Breast cancer cells (MCF7 and MDA-MB-231, 250 cells/well
in a 12-well plate) were treated with 0.25, 0.5, and 1 nmol/L PVP/PTX-SAs and PTX along with their respective controls. On day 14, cells were
rinsed with PBS and stained with hematoxylin to visualize colonies for counting. Photographs of clonogenic pattern were captured in Multimage™
light cabinet. (B) Bar graphs represent number of colonies formed in each treatment group. Data represented as mean 7 standard error of the mean
(n ¼ 3), *Po0.05.
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4. Discussion
The main problem of paclitaxel-based chemotherapy is severe
systemic toxicity due to nonspecific accumulation of anticancer
agent. In other words, administration of paclitaxel with lipophilic
solvents or surfactant(s) may result in insufficient drug levels at the
tumor site or quick clearance due to the aggregation of paclitaxel
nanoformulation. Although literature and clinical evidence suggest
some formulations have exhibited superior therapeutic outcome, a
simple preparative approach like self-assembly formulations of
paclitaxel is preferred39,40. Therefore, the main focus of this study
is to develop paclitaxel/polymer based nanoformulations by self-
assembly technique to enhance the efficacy of paclitaxel in breast
cancer treatment. Polymeric nanoparticles are better alternatives
for drug delivery with improved therapeutic benefits. In this same
regard, we prepared nanoparticle colloidal system with paclitaxel
entrapped in the matrix. The unique structure of the polymeric
matrix provides advantages of delivery and intracellular penetra-
tion. Thus achieving sustained drug release, preventing frequent
administration and overall broad spectrum of therapeutic benefits
are expected41. The unique preparative approach of self-assembly
technique enables formulation scientists to reduce usage of
external excipients and in the process reduces the chances of
toxicity from the nanocarrier itself. It is reported that the super-
iority of self-assembled nanoparticles in the field of drug delivery
is favored39,40. The hydrophilic aqueous polymeric solution serves
as a bed for the hydrophobic drug through van der Waals forces/
interaction or hydrogen bonding at the core of the particle.
Hydrophobic interaction between the hydrophobic polyvinyl group
of PVP and paclitaxel is responsible in the formation of the
nanoformulation. Due to steric stabilization, these nanodrug
formulations have a longer retention in the blood stream whereas
their nanosized structures facilitate the nanoformulation to escape
through the leaky vasculature and release of drug at the tumor sites
owing to their enhanced permeability and retention effect42. Self-
assembled drug nanoparticles have gained significant interest in
the therapeutic field due to biocompatibility43, biodegradability,
and low immunogenic properties44,45. Therefore, in this study, we
examined the ability of eight commonly used pharmaceutical
polymers to generate Poly/PTX-SAs. Among these eight poly-
mers, PVP polymer was not only capable of producing the
smallest size (140.53 nm) with a negative zeta potential
(–6.21 mV, Fig. 1). This formulation was also exhibited lower
toxicity with RBCs (Fig. 2) than PTX alone. Additionally, these
PVP-coumarin 6-SAs exhibited superior interaction with breast
cancer cells compared to other Poly/coumarin 6-SAs (Fig. 3). The
size and zeta potential properties of the PVP/PTX-SAs formulation
resembles clinically-used PTX nanoparticle formulations such as
Abraxane® and Genexol® PM. A negative zeta potential, favorable
for the stability of the nanoparticles, prevent them from binding to
the plasma proteins and prolong their circulation46. Due to these
physicochemical characteristics delivery can be avoided. As it is
the inherent nature of these nanoparticles, they may tend to reach
at the tumor site via enhanced permeation and retention effect47.
However, there was no direct evidence provided through this
article. The self-assembly formation of PVP and PTX was further
confirmed by TEM (particle assembly leads to 53.81 nm) and a
continuous dose-dependent binding profile with paclitaxel in
fluorescence quenching experiments (Fig. 4). From the spectral
analysis, it is confirmed that the presence of chemical functional/
repeating units of PVP and PTX in PVP/PTX-SAs that are found
Figure 7 Preferential cell death induced by PVP/PTX-SAs in MDA-
MB-231 cells. (A) Tubulin stabilization images of polyvinylpyrroli-
done paclitaxel self-assembly. Cells have been treated with equivalent
concentrations of 5 nmol/L PTX or PVP/PTX-SA for 8 h. Imaged by
Carl Zeiss LSM 710. Original magnification 400×. This data suggests
PVP/PTX-SA treatment leads to PTX-induced microtubule stabiliza-
tion. (B) MDA-MB-231 cells were treated with 10 nmol/L PVP/PTX-
SAs or PTX or respective controls for 48 h. Cell lysates were analyzed
to detect levels of Bax, Bid, cleaved caspase 7, cleaved PARP, Bcl-xL,
and MDR1, with β-actin as a control. (C) Densitometry analysis of
Bid, Bax, cleaved caspase 7, cleaved PARP, Bcl-xL, and MDR1 in
MDA-MB-231 cells after 48 h treatment with 10 nmol/L PVP/PTX-
SAs or PTX and their respective controls. The results were consistent
in two independent sets of experiments.
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in the particles, suggesting that the integrity of the polymer(s) and
PTX is maintained in the formulation.
Polyvinylpyrrolidone is widely used as inactive pharmaceutical
excipient for binder/disperser, film former, flavoring liquid, and
adhesive applications for multiple uses such as tablets, capsules,
ophthalmic solution, and transdermal patches. Earlier in 1950s,
PVP was used as a plasma volume expander. More importantly,
PVP is considered as generally safe chemical for many uses by the
U.S. Food and Drug Administration. Thus, it may hold promise in
delivering PTX too. PVP was earlier implemented as a binder/
stabilizer for PTX in a reverse microemulsion48, solvent evapora-
tion49 and nanoprecipitation methods for PTX/PVP-PCL nanopar-
ticles (110 nm)50,51. These studies support our current findings that
PVP is a better choice for holding PTX in self-assembly grooves.
PVP has been used as a solid dispersion for PTX and doce-
taxel52,53. In addition, Sharma et al.48 also developed polyvinyl-
pyrrolidone nanoparticle-encapsulated taxol. Our approach is a
direct self-assembly or solid dispersion method while above
formulation is based on reverse microemulsion method. Based
on our study, we believe that self-assembly of PVP and PTX may
happen due co-precipitation.
In order to further utilize PVP as a self-assembly binder or
delivery carrier for PTX, it is crucial for the nanoparticle to interact
more closely with cancer cells and release effectively into cytosol
for maximizing the pharmacological effects of PTX. Through this
study, we proved that the PVP/PTX-SAs induce a greater amount
of formulation in cancer cells as observed with fluorescence
microscopy and flow cytometry (Fig. 3). In addition, PVP/PTX-
SAs exhibit superior anticancer activity in proliferation and
clonogenic assays against breast cancer cells, compared to PTX
alone (Figs. 5 and 6).
PTX is a classical and unquestioned microtubule inhibitor
which exhibits clinical success. PTX promotes tubulin polymer-
ization and stabilization of microtubules resulting in G2-M phase
arrest and thus mitotic cell death occurs54. Development of
improved tubulin-binding drugs or improving PTX tubulin-bind-
ing and improving the stability of microtubule efficiency with
formulations of any type are considered to be attractive in cancer
therapeutics. In this investigation, we observed that our lead PVP/
PTX-SAs are acting significantly on cell tubulin dynamics and
tubulin polymerization, thus contributing to mitotic block in breast
cancer cells (Fig. 7A)55. This determines the impact of PVP's role
in this formulation as a drug carrier. In cancer therapeutics,
apoptosis induced by the Bcl-2 family is an important parameter
as it allows prediction of the mitochondrial pathway56. In this
regard, our study results showed distinct effects of PVP/PTX-SAs
on apoptotic signaling with reduced expression of Bcl-xL,
profound expression of pro-apoptotic proteins (Bax and Bid),
and the expression profile of cleaved PARP, and cleaved caspase
7, in comparison to control and native drug treatments. This
demonstrates that enhanced apoptotic cell death occurs with PVP/
PTX-SAs treatment than with conventional exposure57. These
results further affirm enhanced toxicity effects of prepared samples
and are well consistent with the results of proliferation and
clonogenic assays.
Altogether, PVP/PTX-SAs demonstrated that these nanoparti-
cles are taken up by breast cancer cells, and induce superior
anticancer activity in breast cancer cells (Scheme 1). Further, PVP
is known to provide extensive stability to the therapeutic mole-
cules and reduction of renal clearance58. These data support the
feasibility of developing PVP/PTX-SAs as nanoparticle-based
therapeutics for improving the therapeutic benefits of PTX. The
shortcome of this study is that there is no direct evidence that our
nanoformulation is directly targeting tumor cells. However, in our
future work, we plan design this PVP/PTX-SAs as targeted drug
delivery technology employing our targeted delivery proto-
cols27,30,33. Developing such targeted nanoformulation is aimed
for intravenous administration. That way we can achieve higher
therapeutic benefits of such self-assembly nanoparticle formulation
through targeted approachability.
5. Conclusions
Introducing clinically relevant PTX (hydrophobic anticancer drug)
into self-assembled nanoparticles was successfully achieved.
Based on particle size, cellular uptake, and hemolysis assays,
PVP/PTX-SAs were found to be better formulations over seven
other Poly/PTX-SAs. We observed superior anticancer effects of
PVP/PTX-SAs through inhibition of proliferation and colony
formation, which were further confirmed by tubulin stabilization
and immunoblot analysis. These findings highlight the advantages
of implementation of PVP/PTX-SAs in comparison to other
conventional PTX formulations. However, further pre-clinical
evidence is needed to confirm the advantages for cancer patients
of such self-assembly systems and to gain mechanistic insights.
Scheme 1 Schematic and hypothetical structural representation of PVP/PTX-SAs. Color, dimensions and assembly are not comparable to
synthesized formulation. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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